Peak / MIC of FQ: clinical data
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Preston et al., J.A.M.A., 1998 Jan 14;279(2):125-9
OBJECTIVE: To prospectively quantitate the relationship between plasma levels of levofloxacin and successful clinical and/or microbiological outcomes and occurrence of adverse events in infected patients.
PATIENTS: 313 with clinical signs and symptoms of bacterial infections of the respiratory tract, skin, or urinary tract.
MAIN OUTCOME MEASURES: Clinical response and microbiological eradication of pathogenic organisms.